Drug news
NICE does not recommend Cyramza (ramucirumab) for GI Cancer- Eli Lilly.
The National Institute for Heath and Care Excellence (NICE) in a consultative document has not recommended Cyramza (ramucirumab) as monotherapy or in combination with paclitaxel for pre-treated, advanced gastric cancer or gastro-oesophageal junction adenocarcinoma. Taking account of the modest results from RAINBOW and REGARD trials in median overall survival and having regard to cost (£42 000 per patient), NICE did not find the drug cost effective.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.